(ABSI) Absci - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 762m USD | Total Return: 91.7% in 12m
Avg Turnover: 24.8M
Qual. Beats: -2
Rev. Trend: -88.7%
Qual. Beats: -3
Warnings
Share dilution 22.9% YoY
Interest Coverage Ratio -857.7 is critical
Altman Z'' -15.00 < 1.0 - financial distress zone
Tailwinds
Leader
Absci Corporation (ABSI) is a Vancouver-based, clinical-stage biotechnology firm specializing in the discovery and development of antibody therapeutics. The company utilizes a generative AI platform to design biologics, aiming to accelerate the traditional drug discovery timeline which typically spans several years before reaching clinical trials.
The firms current pipeline includes ABS-101 for inflammatory bowel disease and ABS-201 for androgenic alopecia, both of which have transitioned into clinical testing phases. Additionally, Absci maintains early-stage programs in immuno-oncology and general oncology. The company’s business model relies heavily on strategic R&D collaborations with major technology and healthcare entities, including Oracle, AMD, and Memorial Sloan Kettering Cancer Center.
In the biotechnology sector, companies often leverage such high-compute partnerships to optimize protein folding simulations and reduce laboratory overhead. For a deeper look into the companys fundamentals, ValueRay provides additional data points for your analysis. Absci continues to focus on its proprietary Integrated Drug Creation platform to identify novel drug candidates.
- Data generative AI platform efficacy drives high-value pharmaceutical partnership milestones
- Clinical trial data for ABS-101 determines inflammatory bowel disease market viability
- Strategic R&D collaborations with NVIDIA and AstraZeneca validate platform scalability
- Cash burn rate and capital runway influence near-term equity financing needs
- Expansion of antibody therapeutic pipeline accelerates long-term royalty revenue potential
| Net Income: -118.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.50 > 0.02 and ΔFCF/TA -17.32 > 1.0 |
| NWC/Revenue: 6.10k% < 20% (prev 2.67k%; Δ 3.42k% < -1%) |
| CFO/TA -0.50 > 3% & CFO -97.4m > Net Income -118.4m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 6.59 > 1.5 & < 3 |
| Outstanding Shares: last quarter (153.0m) vs 12m ago 22.90% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.86% > 50% (prev 2.07%; Δ -1.21% > 0%) |
| Interest Coverage Ratio: -857.7 > 6 (EBITDA TTM -115.5m / Interest Expense TTM 148k) |
| A: 0.57 (Total Current Assets 132.0m - Total Current Liabilities 20.0m) / Total Assets 195.6m |
| B: -3.35 (Retained Earnings -654.4m / Total Assets 195.6m) |
| C: -0.59 (EBIT TTM -126.9m / Avg Total Assets 214.0m) |
| D: -27.69 (Book Value of Equity -654.1m / Total Liabilities 23.6m) |
| Altman-Z'' = -40.21 = D |
As of May 24, 2026, the stock is trading at USD 5.10 with a total of 2,241,735 shares traded.
Over the past week, the price has changed by -0.58%,
over one month by +38.59%,
over three months by +92.45% and
over the past year by +91.73%.
Absci has received a consensus analysts rating of 4.56. Therefore, it is recommended to buy ABSI.
- StrongBuy: 5
- Buy: 4
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 8.8 | 71.8% |
P/B = 4.4876
Revenue TTM = 1.84m USD
EBIT TTM = -126.9m USD
EBITDA TTM = -115.5m USD
Long Term Debt = 2.15m USD (estimated: total debt 4.42m - short term 2.27m)
Short Term Debt = 2.27m USD (from shortTermDebt, last quarter)
Debt = 8.42m USD (from shortLongTermDebtTotal, last quarter) + Leases 4.00m
Net Debt = -117.3m USD (calculated: Debt 8.42m - CCE 125.7m)
Enterprise Value = 645.1m USD (762.4m + Debt 8.42m - CCE 125.7m)
Interest Coverage Ratio = -857.7 (Ebit TTM -126.9m / Interest Expense TTM 148k)
EV/FCF = -6.55x (Enterprise Value 645.1m / FCF TTM -98.5m)
FCF Yield = -15.27% (FCF TTM -98.5m / Enterprise Value 645.1m)
FCF Margin = -5.37k% (FCF TTM -98.5m / Revenue TTM 1.84m)
Net Margin = -6.45k% (Net Income TTM -118.4m / Revenue TTM 1.84m)
Gross Margin = unknown ((Revenue TTM 1.84m - Cost of Revenue TTM 11.7m) / Revenue TTM)
Tobins Q-Ratio = 3.30 (Enterprise Value 645.1m / Total Assets 195.6m)
Interest Expense / Debt = 1.76% (Interest Expense 148k / Debt 8.42m)
Taxrate = 21.0% (US default 21%)
NOPAT = -100.3m (EBIT -126.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 6.59 (Total Current Assets 132.0m / Total Current Liabilities 20.0m)
Debt / Equity = 0.05 (Debt 8.42m / totalStockholderEquity, last quarter 172.0m)
Debt / EBITDA = 1.02 (negative EBITDA) (Net Debt -117.3m / EBITDA -115.5m)
Debt / FCF = 1.19 (negative FCF - burning cash) (Net Debt -117.3m / FCF TTM -98.5m)
Total Stockholder Equity = 186.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -55.34% (Net Income -118.4m / Total Assets 195.6m)
RoE = -14.09% (Net Income TTM -118.4m / Total Stockholder Equity 840.7m)
RoCE = -15.06% (EBIT -126.9m / Capital Employed (Equity 840.7m + L.T.Debt 2.15m))
RoIC = -192.4% (out of range, set to none) (NOPAT -100.3m / Invested Capital 52.1m)
WACC = 14.61% (E(762.4m)/V(770.8m) * Re(14.76%) + D(8.42m)/V(770.8m) * Rd(1.76%) * (1-Tc(0.21)))
Discount Rate = 14.76% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 100.00 | Cagr: 25.01%
[DCF] Fair Price = unknown (Cash Flow -98.5m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.89 | # QB: -2
Revenue Correlation: -88.70 | Revenue CAGR: -34.35% | SUE: -1.95 | # QB: -3
EPS current Quarter (2026-06-30): EPS=-0.20 | Chg30d=+2.75% | Revisions=+14% | Analysts=6
EPS next Quarter (2026-09-30): EPS=-0.20 | Chg30d=-3.36% | Revisions=-14% | Analysts=6
EPS current Year (2026-12-31): EPS=-0.76 | Chg30d=+3.72% | Revisions=+14% | GrowthEPS=+13.3% | GrowthRev=+131.0%
EPS next Year (2027-12-31): EPS=-0.62 | Chg30d=+0.65% | Revisions=+25% | GrowthEPS=+18.3% | GrowthRev=+206.6%
[Analyst] Revisions Ratio: +25%